

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gary L. Olson et al.

Serial No.: 10/001,945

Filed: November 1, 2001

For: "Therapeutic Agents and Methods of Use

Thereof for the Modulation of Angiogenesis"

Attorney Docket No.: PPI-106CP2

Mailstop: Sequence

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1653

Examiner: Not Yet Assigned

TECH CENTER 1600/2900

"Ex	press Ma	il" Mailing Label Number_	EV 244 880 048 US	
		•.	June 17 2003	

June 17, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mailstop: Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signatu

Conti, Jr., Registration No. 31,503

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the above-identified patent application, please amend the application as follows.

In the specification:

Please replace the paragraph at page 14, lines 3-13 with:

--In certain embodiments, P is an amino acid sequence selected from the group consisting of Ac-Pro-Leu-Gly-Met-Trp-Ala (SEQ ID NO:24); Gly-Pro-Leu-Gly-Met-His-Ala-Gly (SEQ ID NO:25); Gly-Pro-Leu-(Me)Gly (SEQ ID NO:26); Gly-Pro-Leu-Gly (SEQ ID NO:27); Gly-Met-Gly-Leu-Pro (SEQ ID NO:28); Ala-Met-Gly-Ile-Pro (SEQ ID NO:29); Gly-Arg-Gly-Asp-(O-Me-Tyr)-Arg-Glu (SEQ ID NO:30); Gly-Arg-Gly-Asp-Ser-Pro (SEQ ID NO:31); Gly-Arg-Gly-